Literature DB >> 27493259

Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context.

Wouter N Leonhard1, Hester Happe1, Dorien J M Peters2.   

Abstract

Patients with autosomal dominant polycystic kidney disease (ADPKD) typically carry a mutation in either the PKD1 or PKD2 gene, which leads to massive cyst formation in both kidneys. However, the large intrafamilial variation in the progression rate of ADPKD suggests involvement of additional factors other than the type of mutation. The identification of these factors will increase our understanding of ADPKD and could ultimately help in the development of a clinically relevant therapy. Our review addresses the mechanisms by which various biologic processes influence cyst formation and cyst growth, thereby explaining an important part of the inter- and intrafamilial variability in ADPKD. Numerous studies from many laboratories provide compelling evidence for the influence on cyst formation by spatiotemporal gene inactivation, the genetic context, the metabolic status, the presence of existing cysts, and whether the kidneys were challenged by renal injury. Collectively, a solid basis is provided for the concept that the probability of cyst formation is determined by functional PKD protein levels and the biologic context. We model these findings in a graphic representation called the cystic probability landscape, providing a robust conceptual understanding of why cells sometimes do or do not form cysts.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  ADPKD; Biological Context; PKD1; Polycystin; Probability Landscape; polycystic kidney disease

Mesh:

Substances:

Year:  2016        PMID: 27493259      PMCID: PMC5118495          DOI: 10.1681/ASN.2016040425

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  74 in total

Review 1.  Autosomal dominant polycystic kidney disease--more than a renal disease.

Authors:  P A Gabow
Journal:  Am J Kidney Dis       Date:  1990-11       Impact factor: 8.860

2.  Do human chromosomal bands 16p13 and 22q11-13 share ancestral origins?

Authors:  R H Giles; H G Dauwerse; G J van Ommen; M H Breuning
Journal:  Am J Hum Genet       Date:  1998-10       Impact factor: 11.025

3.  Generalized lacZ expression with the ROSA26 Cre reporter strain.

Authors:  P Soriano
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

4.  The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I.

Authors:  F Qian; T J Watnick; L F Onuchic; G G Germino
Journal:  Cell       Date:  1996-12-13       Impact factor: 41.582

5.  PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice.

Authors:  Ali K Ahrabi; Sara Terryn; Giovanna Valenti; Nathalie Caron; Claudine Serradeil-Le Gal; Danielle Raufaste; Soren Nielsen; Shigeo Horie; Jean-Marc Verbavatz; Olivier Devuyst
Journal:  J Am Soc Nephrol       Date:  2007-05-02       Impact factor: 10.121

6.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

7.  Pkd1 haploinsufficiency increases renal damage and induces microcyst formation following ischemia/reperfusion.

Authors:  Ana P Bastos; Klaus Piontek; Ana M Silva; Dino Martini; Luis F Menezes; Jonathan M Fonseca; Ivone I Fonseca; Gregory G Germino; Luiz F Onuchic
Journal:  J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 10.121

8.  Retinoic acid-dependent activation of the polycystic kidney disease-1 (PKD1) promoter.

Authors:  M Rafiq Islam; Sanjeev Puri; Marianna Rodova; Brenda S Magenheimer; Robin L Maser; James P Calvet
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-15

9.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

Authors:  Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth
Journal:  Gastroenterology       Date:  2009-07-29       Impact factor: 22.682

10.  Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury.

Authors:  Sony Prasad; John Patrick McDaid; Frederick Wai Keung Tam; John Lionel Haylor; Albert Chee Meng Ong
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

View more
  16 in total

1.  Multiple unilateral subcapsular cortical hemorrhagic cystic disease of the kidney: CT and MRI findings and clinical characteristic.

Authors:  Kotaro Yoshida; Naoki Takahashi; Bernard F King; Akira Kawashima; Peter C Harris; Lynn D Cornell; Emilie Cornec-Le Gall; Dai Inoue; Ichiro Mizushima; Mitsuhiro Kawano; Eric Thervet; Paul René de Cotret; Vicente E Torres
Journal:  Eur Radiol       Date:  2019-02-26       Impact factor: 5.315

2.  Loss of function of renal Glut2 reverses hyperglycaemia and normalises body weight in mouse models of diabetes and obesity.

Authors:  Leticia Maria de Souza Cordeiro; Lauren Bainbridge; Nagavardhini Devisetty; David H McDougal; Dorien J M Peters; Kavaljit H Chhabra
Journal:  Diabetologia       Date:  2022-03-15       Impact factor: 10.460

3.  Renal plasticity revealed through reversal of polycystic kidney disease in mice.

Authors:  Ke Dong; Chao Zhang; Xin Tian; Daniel Coman; Fahmeed Hyder; Ming Ma; Stefan Somlo
Journal:  Nat Genet       Date:  2021-10-11       Impact factor: 41.307

4.  Identification and functional interpretation of miRNAs affected by rare CNVs in CAKUT.

Authors:  Kristina Mitrovic; Ivan Zivotic; Ivana Kolic; Ana Djordjevic; Jelena Zakula; Jelena Filipovic Trickovic; Maja Zivkovic; Aleksandra Stankovic; Ivan Jovanovic
Journal:  Sci Rep       Date:  2022-10-22       Impact factor: 4.996

Review 5.  Targeting angiogenesis and lymphangiogenesis in kidney disease.

Authors:  Katsuyuki Tanabe; Jun Wada; Yasufumi Sato
Journal:  Nat Rev Nephrol       Date:  2020-03-06       Impact factor: 28.314

Review 6.  Polycystic kidney features of the renal pathology in glycogen storage disease type I: possible evolution to renal neoplasia.

Authors:  Monika Gjorgjieva; Laure Monteillet; Julien Calderaro; Gilles Mithieux; Fabienne Rajas
Journal:  J Inherit Metab Dis       Date:  2018-06-04       Impact factor: 4.982

Review 7.  Emerging Therapies for Childhood Polycystic Kidney Disease.

Authors:  William E Sweeney; Ellis D Avner
Journal:  Front Pediatr       Date:  2017-04-19       Impact factor: 3.418

8.  Novel long-range regulatory mechanisms controlling PKD2 gene expression.

Authors:  Stéphanie Moisan; Stéphanie Levon; Emilie Cornec-Le Gall; Yannick Le Meur; Marie-Pierre Audrézet; Josée Dostie; Claude Férec
Journal:  BMC Genomics       Date:  2018-07-03       Impact factor: 3.969

9.  Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.

Authors:  Wouter N Leonhard; Xuewen Song; Anish A Kanhai; Ioan-Andrei Iliuta; Andrea Bozovic; Gregory R Steinberg; Dorien J M Peters; York Pei
Journal:  EBioMedicine       Date:  2019-08-28       Impact factor: 8.143

10.  Four-jointed knock-out delays renal failure in an ADPKD model with kidney injury.

Authors:  Chiara Formica; Hester Happé; Kimberley Am Veraar; Andrea Vortkamp; Marion Scharpfenecker; Helen McNeill; Dorien Jm Peters
Journal:  J Pathol       Date:  2019-06-17       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.